Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Express Scripts
Merck
Healthtrust
Boehringer Ingelheim
Julphar
US Army
Baxter
Mallinckrodt
Farmers Insurance

Generated: January 23, 2018

DrugPatentWatch Database Preview

Hoffmann La Roche Company Profile

« Back to Dashboard

Summary for Hoffmann La Roche
International Patents:416
US Patents:15
Tradenames:12
Ingredients:11
NDAs:14

Drugs and US Patents for Hoffmann La Roche

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche BONIVA ibandronate sodium TABLET;ORAL 021455-002 Mar 24, 2005 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Hoffmann La Roche ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER ceftriaxone sodium INJECTABLE;INJECTION 050624-003 Feb 11, 1987 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Hoffmann La Roche FORTOVASE saquinavir CAPSULE;ORAL 020828-001 Nov 7, 1997 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Hoffmann La Roche BONIVA ibandronate sodium TABLET;ORAL 021455-002 Mar 24, 2005 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Hoffmann La Roche ROCEPHIN ceftriaxone sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 050585-001 Dec 21, 1984 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Hoffmann La Roche ACCUTANE isotretinoin CAPSULE;ORAL 018662-004 Mar 28, 1983 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Hoffmann La Roche XENICAL orlistat CAPSULE;ORAL 020766-001 Apr 23, 1999 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Hoffmann La Roche

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-002 Apr 30, 1998 ➤ Subscribe ➤ Subscribe
Hoffmann La Roche FORTOVASE saquinavir CAPSULE;ORAL 020828-001 Nov 7, 1997 ➤ Subscribe ➤ Subscribe
Hoffmann La Roche ACCUTANE isotretinoin CAPSULE;ORAL 018662-003 May 7, 1982 ➤ Subscribe ➤ Subscribe
Hoffmann La Roche ACCUTANE isotretinoin CAPSULE;ORAL 018662-002 May 7, 1982 ➤ Subscribe ➤ Subscribe
Hoffmann La Roche BONIVA ibandronate sodium TABLET;ORAL 021455-001 May 16, 2003 ➤ Subscribe ➤ Subscribe
Hoffmann La Roche VALCYTE valganciclovir hydrochloride FOR SOLUTION;ORAL 022257-001 Aug 28, 2009 ➤ Subscribe ➤ Subscribe
Hoffmann La Roche ROMAZICON flumazenil INJECTABLE;INJECTION 020073-001 Dec 20, 1991 ➤ Subscribe ➤ Subscribe
Hoffmann La Roche ACCUTANE isotretinoin CAPSULE;ORAL 018662-004 Mar 28, 1983 ➤ Subscribe ➤ Subscribe
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-002 Apr 30, 1998 ➤ Subscribe ➤ Subscribe
Hoffmann La Roche ACCUTANE isotretinoin CAPSULE;ORAL 018662-004 Mar 28, 1983 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for HOFFMANN LA ROCHE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe For Oral Solution 50 mg/mL ➤ Subscribe 3/21/2011
➤ Subscribe Tablets 150 mg and 500 mg ➤ Subscribe 11/10/2008
➤ Subscribe Injection 1 mg/mL, 3 mL Vial ➤ Subscribe 8/31/2007
➤ Subscribe Tablets 2.5 mg and 150 mg ➤ Subscribe 5/16/2007
➤ Subscribe Tablets 450 mg ➤ Subscribe 12/27/2005
Premature patent expirations for HOFFMANN LA ROCHE

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Subscribe ➤ Subscribe

Non-Orange Book US Patents for Hoffmann La Roche

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,530,661 Process for the manufacture of pharmaceutically active compounds ➤ Subscribe
6,627,221 Pharmaceutical composition containing diphosphonic acid or salt thereof ➤ Subscribe
8,329,724 Process for the manufacture of pharmaceutically active compounds ➤ Subscribe
8,067,434 Compounds and methods for development of Ret modulators ➤ Subscribe
7,846,941 Compounds modulating c-kit and c-fms activity and uses therefor ➤ Subscribe
8,415,469 Compounds and methods for kinase modulation, and indications therefor ➤ Subscribe
9,663,517 Compositions and uses thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Hoffmann La Roche Drugs

Supplementary Protection Certificates for Hoffmann La Roche Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00071 Netherlands ➤ Subscribe PRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920
C0048 Belgium ➤ Subscribe PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
2012000043 Germany ➤ Subscribe PRODUCT NAME: VEMURAFENIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
C/GB98/044 United Kingdom ➤ Subscribe PRODUCT NAME: ORLISTAT; REGISTERED: UK EU/1/98/071/001 19980729; UK EU/1/98/071/002 19980729; UK EU/1/98/071/003 19980729; UK EO/1/98/071/004 19980729; UK EU/1/98/071/005 19980729; UK EU/1/98/071/006 19980729
00045 Netherlands ➤ Subscribe PRODUCT NAME: CAPECITABINE,DESGEWENST IN DE VORM VAN EEN SOLVAAT; NATL REGISTRATION NO/DATE: EU/1/00/163/001-002 20010202; FIRST REGISTRATION: CH 54657 19980610
01C/021 Belgium ➤ Subscribe PRODUCT NAME: CAPECITABINE, NATL REGISTRATION NO/DATE: EU/1/00/163/001 20010205; FIRST REGISTRATION: CH 54657 19980610
C/GB02/027 United Kingdom ➤ Subscribe PRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425
035 Luxembourg ➤ Subscribe 92035, EXPIRES: 20270217
12/025 Ireland ➤ Subscribe PRODUCT NAME: VEMURAFENIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
2012010,C1893612 Lithuania ➤ Subscribe PRODUCT NAME: VEMURAFENIBUM; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Deloitte
Medtronic
Covington
Farmers Insurance
Cerilliant
Citi
QuintilesIMS
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot